$ALM

Why is Almonty Industries stock rallying today?

Almonty Industries (ALM) stock rose 2.7% in pre-market trading to $12.74. Stifel initiated coverage with a Buy rating and $25 target, while Goldman Sachs gave a Neutral rating and $13 target. The company's Sangdong mine in South Korea received final certification for commercial operations, securing 90% of Phase I output under long-term agreements. The S&P 500, Dow Jones, and Nasdaq were up 0.3%, 0.3%, and 0.5% respectively.

Original reporting
Published Sep 25, 2026, 12:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ALM
Bullish
high confidence
Mentioned
$ALM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALMBullishHigh
01

Why it matters

Analyst coverage and certification provide a fresh catalyst that could drive short‑term price appreciation and longer‑term valuation re‑rating.

02

Market read

The news adds a new catalyst for ALM, potentially influencing mining sector sentiment and commodity exposure.

03

What to watch

Potential operational risks at the new mine and reliance on long‑term offtake contracts could limit upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Almonty Industries is a mid‑cap miner focused on tungsten, recently achieving commercial certification for its Sangdong mine in South Korea.

Company-level read

Ticker impact

$ALMBullishHigh confidence
Context

Stifel and Goldman Sachs initiated coverage with divergent ratings and price targets, and Almonty's Sangdong mine received final commercial certification, driving a 2.7% pre‑market rally.

Expected impact

Potential upside toward $20‑$25 range if momentum sustains.

Evidence & confidence

Buy rating with $25 target implies ~100% upside; certification unlocks revenue stream.

Market effects

Highlights growing interest in tungsten supply chain diversification, may benefit peers in mining and critical minerals.

Positive for South Korean mining sector and related commodity markets.

Adds to broader narrative of resource security driving investor attention.

Counterpoint

Goldman Sachs' neutral rating and $13 target suggest valuation concerns; investors may wait for price to test lower levels.

Key entities

  • Almonty Industries

    Tungsten mining company (ticker ALM).

  • Stifel

    Initiated coverage with a Buy rating and $25 price target.

  • Goldman Sachs

    Initiated coverage with a Neutral rating and $13 price target.

Related articles

$ALMMed

Defense Stockpile Orders Send Explorers Back to Old Tungsten Camps

The U.S. Defense Logistics Agency awarded a $2B contract for tungsten supplies, with a $450M investment from the Department of War. GoldHaven Resources (CSE: GOH) completed drilling at its Kuhn tungsten-skarn target, intersecting skarn mineralization in two locations. Almonty Industries (NASDAQ: ALM) began commercial operations at its Sangdong plant, with 90% of Phase I production contracted. Guardian Metal (NYSE: GMTL) reported drilling results from its Tempiute project.

$ELMTMed

Technology Metals Report (10.04.2026): A Summit Without a Rare Earth Deal Leaves the West Buying Its Way to Supply

The U.S. and China failed to reach a rare earth supply deal during Xi Jinping's visit, leaving the West to secure supplies. Rare earth exports from China to the U.S. declined, with prices showing mixed trends. Elmet Group and Almonty Industries are expanding tungsten production. Glencore will partner with the U.S. strategic minerals reserve. Eramet plans to expand lithium production in Argentina. Processing capacity is also increasing, with Korea Zinc planning a U.S. smelter.

$ALMMed

Almirall, S.A.: Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

Almirall, S.A. (ALM) presented new clinical data at EADV 2026, showcasing advances in dermatology treatments. Key findings include sustained improvements in atopic dermatitis with lebrikizumab and benefits in psoriasis with tildrakizumab. The company also highlighted its commitment to medical dermatology through sponsorship and awareness campaigns.

$ALMMed

Almonty Industries ALM Stock Rallies On Tungsten Breakout

Almonty Industries (NASDAQ: ALM) stock rose 11.09% on positive tungsten market news and project progress. The company reported $42.99M in quarterly revenue, $1.22B in cash, and a share buyback plan. ALM secured inspection certificates for its Sangdong project in South Korea and expanded operations in Rwanda, positioning itself as a key tungsten supplier outside China.